PDCD1 and cancer: In recent years, oncology patients have reason to hope thanks to the advancement of immunotherapy for cancers, particularly immune checkpoint inhibitor (ICI) therapies like anti-programmed cell death-1 (anti-PD-1) and programmed death-ligand 1 (PD-L1), which have the greatest potential for application.